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ABSTRACT
Background: Pertussis is a highly contagious respira-
tory disease. Despite a high rate of vaccine coverage 
through the Dutch national immunization program,
the incidence of pertussis remains high in the Netherlands
and the risk of infection continues. Because pertussis is
most severe in unimmunized infants and infants who 
have only received some of the recommended doses,
new pertussis immunization strategies should be con-
sidered to protect this vulnerable population.
Objective: This study was designed to estimate the 
cost-effectiveness of 3 new immunization strategies for 
possible addition to the current Dutch national immu-
nization program: immunization of the infant at birth, 
immunization of the parents immediately after birth of 
the child (cocooning), and maternal immunization dur-
ing the third trimester of pregnancy.
Methods: A literature search was performed in the 
PubMed database for articles published in English,
German, and Dutch using the following terms: pertussis,
whooping cough, vaccination strategies, maternal im-
munization, cocooning, at birth, vaccine efficacy, mor-
tality, underreporting, prevalence, incidence, and
cost-effectiveness. A decision-tree model was developed 
for this analysis, and data on pertussis morbidity and
costs were collected consistently for different age groups 
(infants <1 year of age and adults 25 to 34 years of 
age). The size of the infant cohort was set at 200,000
to approximate previous Dutch birth cohorts. The size 
of the adult cohort was set at 401,380 parents for the
cocooning strategy and 201,380 mothers for the ma-
ternal immunization strategy. Health benefits (quality-
adjusted life-years [QALYs]) and costs were estimated 
in both cohorts for each of the 3 immunization strate-
gies. Incremental cost-effectiveness ratios were calculated 
from both a payer’s and a societal perspective. The
robustness of the results was determined through sen-
sitivity analysis.
Results: In the base-case analysis, cocooning and
maternal immunization were found to be effective in 
reducing the incidence of pertussis among infants (123
and 174 infant cases were expected to be prevented,
respectively). Furthermore, cocooning and maternal 
immunization were estimated to be cost-effective from 
a payer’s perspective (€4600 [US $6400]/QALY and
€3500 [$4900]/QALY, respectively) and even cost-saving 
from a societal perspective (savings of up to €7200
[$10,100] and €5000 [$7000], respectively). Sensitivity 
analyses revealed that favorable cost-effectiveness was
generally robust. In the sensitivity analysis, the cost-
effectiveness of cocooning and maternal immunization
was mostly sensitive for changes in assumptions on
underreporting (200-fold increase in reported number
of symptomatic cases) of pertussis disease and infection. 
With no underreporting, the ICER was estimated at
€211,900 ($296,700)/QALY for cocooning and €81,600 
($114,200)/QALY for maternal immunization from a 
payer’s perspective. However, even at much lower levels 
of underreporting (20- to 30-fold increase in incidence), 
cost-effectiveness remained favorable. The cost-
effectiveness of the third strategy, at-birth immunization, 
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implemented pertussis immunization programs for 
adolescents.12,13 Other immunization strategies, such
as universal adult immunization and immunization of 
“new” fathers and mothers, also have been proposed 
in the literature to further reduce the incidence of per-
tussis among infants.6
In the Netherlands, infants have been immunized 
against pertussis routinely since 1953, resulting in a
rapid decrease in the incidence and mortality of the
disease (eg, a 5-fold decrease in pertussis mortality was 
observed during the period 1953–1958).14 The current 
infant pertussis vaccination schedule consists of 3 doses
of the vaccine at 2, 3, and 4 months of age and 2 booster
vaccinations at 11 months and 4 years of age.15 The
Dutch national immunization program has reported
coverage of ~96% of the population.
Despite these efforts, the incidence of pertussis in 
adolescents and adults has increased during the past 
decade; an increase (~2-fold) was seen in these age 
groups during the period 2006 to 2008.16,17 It has been 
suggested that vaccine-induced immunity wanes after 
~4 to 12 years.18 Introduction of the additional booster 
vaccination at the age of 4 years in 2001 has led to a 
significant reduction in pertussis cases among children
4 to 10 years of age.15 However, mainly due to waning
immunity, the incidence among adolescents and adults
remains high. This is a cause for concern because parents
potentially represent an important source of transmis-
sion of pertussis to their infants with increased risks for
severe disease.10,19,20 Therefore, additional pertussis
immunization strategies should be considered to protect 
and reduce the incidence of pertussis among this 
population.
This article investigates 3 such strategies: vaccination 
of the infant at birth, vaccination of both parents im-
mediately after birth of the child (cocooning), and 
vaccination of the mother in the third trimester of 
pregnancy (maternal immunization). Clinical trials have
been performed to estimate the effectiveness and toler-
ability of vaccinating adults and the immunogenicity 
and tolerability of at-birth immunization; however, no 
clinical trials in pregnant women have been pub-
lished.21–24 Currently, only the cocooning strategy could 
be implemented because no vaccine has yet been licensed 
for use in newborns or pregnant women.
If clinically effective, immunization at birth could be
an attractive strategy because it would directly increase
the protection of the most vulnerable group against 
pertussis and could therefore significantly lower the 
was highly unfavorable (€329,900 [$461,900]/QALY 
from a payer’s perspective and €330,100 [$462,100]/
QALY from a societal perspective).
Conclusions: This study estimated that the addition
of cocooning or maternal immunization to the current 
Dutch national immunization program likely would be 
cost-effective or even cost-saving. These estimates were
mainly due to reduction in the number of cases among
parents, which are likely to be mild and therefore would
largely remain unreported. Immunization at birth was 
not a cost-effective strategy. Cocooning was the most 
expensive intervention to implement; however, it resulted
in the highest number of QALYs gained (mainly in
adults). Maternal immunization would offer better 
protection of infants, due to maternally acquired anti-
bodies. (Clin Ther. 2010;32:1479–1495) © 2010
Excerpta Medica Inc.
Key words: pertussis, cost-effectiveness, immuniza-
tion, cocooning, maternal, booster.
INTRODUCTION
Pertussis is a highly contagious respiratory disease
caused by the bacteria Bordetella pertussis and occa-
sionally B parapertussis.1 Transmission occurs primarily
through contact with respiratory droplets or secretions
from infected persons.2 Pertussis infection in adolescents
and adults is generally mild and passes unnoticed3; as 
a consequence, pertussis is highly underreported in these
age groups.3,4 However, pertussis infection is severe in 
infants, in whom it can cause serious morbidity and 
even death.5 Pertussis vaccination programs have been 
implemented, but unvaccinated infants, partly vaccinated 
infants (ie, those who have received only some of the 
recommended doses), and individuals from groups that
refuse vaccination for various reasons (including reli-
gious beliefs) remain at risk.
Implementation of childhood immunization programs
has greatly reduced the burden of pertussis among in-
fants and young children worldwide; ~760,000 deaths 
worldwide are prevented annually.6 However, the inci-
dence among adolescents and adults remains high (eg,
0.1–200 cases per 100,000), and cases of pertussis in 
these groups are important sources of infection for
unvaccinated and partly vaccinated infants.7–11 Ap-
proximately 150,000 cases of pertussis are reported
annually by the World Health Organization.12 To reduce 
transmission of the bacteria in the general population, 
some countries (eg, France, Australia) have already 
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<€20,000 (US $28,000) per quality-adjusted life-year
(QALY) from a societal perspective.31 
Vaccination Strategies
For immunization at birth, it was assumed that
protection was not achieved until 2 weeks after admin-
istration of the first vaccine dose.32 For subsequent 
doses at 2, 3, and 4 months of age, vaccine effectiveness
was immediately increased to the respective higher
levels. Because no Phase III studies in this age group 
have yet been published, vaccine effectiveness was ex-
trapolated from Dutch incidence data and Swedish and 
US follow-up studies.33,34 Based on the Dutch incidence 
data, it was estimated that the vaccine effectiveness after 
administration of the first, second, and third doses
would be ~40%, 70%, and 89%, respectively. These
effectiveness estimates are consistent with previous
observational studies in which the vaccine effectiveness
was estimated at ~30% to 50% after the first dose. 
Therefore, a maximum vaccine effectiveness of 89% 
was assumed after administration of the third dose of 
4 doses at 3 months of age. It was also assumed that
the fourth dose did not further increase the vaccine
effectiveness. Therefore, after 4 months, the vaccination 
program already in place was assumed to provide the
maximum degree of protection, with the fourth dose 
effectively prolonging the duration of protection to the 
maximum assumed.
For the cocooning strategy, it was assumed that fathers
would be vaccinated during the pregnancy and mothers 
would be vaccinated immediately after delivery. In terms
of transmitting pertussis from the mother to the infant,
a delay of 2 weeks was assumed to achieve full effective-
ness of the vaccine in the mother. Implementation of this 
strategy was assumed to reduce the incidence of pertussis
among both the vaccinated adults and their newborns. 
In adults, a vaccine effectiveness of 89% was assumed.18,22
In the Netherlands, mothers and fathers were estimated 
to be the source of infection in ~38% and 17% of infant
cases of pertussis, respectively; therefore, effectiveness
in infants was set at 49% (ie, [38 + 17]  .89).8,17,35
Because of the 2-week delay in achieving full effective-
ness in the mother, infants (during the first 2 weeks of 
life) were assumed to only be protected from transmis-
sion of the disease from the father.
For the maternal immunization strategy, it was as-
sumed that mothers were vaccinated during the third 
trimester of pregnancy and that the effectiveness of the
immunization would be 89% (in both the mother and
burden of the disease.23–25 However, because of the 
delay between immunization and vaccine-induced im-
munity (discussed in the next section), immunization 
at birth will never provide protection immediately after
birth.24,26
Because mothers have been identified as the most 
important source of infection, immunization of mothers
during pregnancy (maternal immunization) may con-
siderably reduce pertussis transmission to newborns. 
Furthermore, infants might be protected by antibodies 
acquired from the mother (immunoglobulin G). How-
ever, there might be reluctance to implement maternal 
immunization because of safety concerns for the unborn
child. Another feasible strategy would be immunization
of both parents during pregnancy or immediately after 
delivery to protect infants from the 2 main sources of 
infection (cocooning).10,26–29 The latter approach might 
eliminate concerns about the safety of the immunization
strategy and might therefore be more acceptable.
Before implementing any vaccination strategy, it is 
important to determine the cost-effectiveness of the 
intervention. The aim of this study was to estimate the 
cost-effectiveness of each of the 3 vaccination strategies—
immunization at birth, cocooning, and maternal immu-
nization—as potential additions to the current immu-
nization program in the Netherlands.
PATIENTS AND METHODS
A literature search was performed in the PubMed da-
tabase for articles published in English, German, and 
Dutch using the following terms: pertussis, whooping 
cough, vaccination strategies, maternal immunization, 
cocooning, at birth, vaccine efficacy, mortality, under-
reporting, prevalence, incidence, and cost-effectiveness. 
Articles were selected on the basis of relevance. Articles
publishing Dutch data were preferred; if unavailable, 
articles publishing data from other western countries 
were used. A decision-analytic model was designed to 
estimate the incremental cost-effectiveness ratio (ICER) 
of adding one of these immunization strategies to the 
current immunization program. Each strategy was
compared with the current Dutch pertussis vaccination
schedule (5 doses) using an acellular pertussis vaccine. 
Furthermore, a direct comparison of costs and health 
gains was made between the different strategies. In ac-
cordance with the Dutch guidelines, future health out-
comes and costs were discounted at rates of 1.5% and
4.0%, respectively.30 As a benchmark, an intervention
was considered to be cost-effective if the ICER was
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of the 3 immunization strategies. Because adverse events
due to acellular pertussis vaccine are uncommon (eg, 
incidence of fever >37.5°C [99.5°F], 5.5%–8.0% of 
recipients) and generally mild (eg, incidence of severe
[grade 3] symptoms, 2.5%–2.8%), associated QALY 
losses and costs were not included in the analysis.13,44,45
The decision tree was constructed in TreeAge Data 
Pro™, version 4.0 (TreeAge Software Inc., Williamstown,
Massachusetts).
Costs, savings, and health gains were calculated over
an 8-year period (matching the assumed duration of 
protection in adults) in the 2 cohorts simultaneously:
infants <1 year of age and adults 25 to 34 years of age. 
The size of the infant cohort was set at 200,000 to ap-
proximate previous Dutch birth cohorts. The size of the
adult cohort was set at 401,380 parents for the cocoon-
ing strategy and 201,380 mothers for the maternal 
immunization strategy. These cohort sizes included the 
risk of spontaneous abortions in the model, next to 
numbers of parents in line with the assumed infant
cohort size.46 Immunization at birth was assumed to
affect only the cohort of newborns, whereas cocooning 
and maternal immunization were assumed to affect 
the newborn).22 The unborn child was assumed to ac-
quire protective maternal antibodies and, therefore,
may be protected immediately after birth, both by the 
antibodies and as a consequence of reduced risk of 
transmission from the mother.36–42 Protection provided
by maternally acquired antibodies in infants was as-
sumed to last 4 months,43 which bridged the gap to
where protection was assumed from the immunization
program already in place. Furthermore, it was assumed 
that, because of the rapid decrease in antibody titers 
after 6 to 12 months, the vaccination only protected 
the infant of the current pregnancy.
In all 3 strategies, vaccine-induced protection against
disease was assumed to last 8 years in adults.18 With a 
possible duration of protection for infection being much
shorter (~2 years) and the optimal interval of revaccina-
tion still being investigated, the calculations for both 
cocooning and maternal immunization should be con-
sidered to apply to first pregnancies only. 
Model
A decision-tree model (Figure 1) was developed to

















Figure 1. Generic decision tree used for calculation of the cost-effectiveness of potential pertussis immuniza-
tion strategies. 
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higher than the number of reported cases in that age 
group. Pertussis in infants is generally severe and there-
fore likely to be reported; hence, it was assumed con-
servatively that no further underreporting occurred in
this age group. Data on pertussis-related hospitalizations 
and admissions to the intensive-care unit were obtained
from 2 Dutch hospital databases—Prismant (Utrecht, 
the Netherlands) and Pediatric Intensive Care Unit 
(Rotterdam, the Netherlands), respectively.
In the period 1998 to 2005, five pertussis-related
deaths were reported among infants (all were 0 to 3
months of age).15,46 The mortality risk was calculated
from these data. An overview of the pertussis incidence
and hospitalization data used in the base-case analysis 
is presented in Table I.52,53
Utilities
Lee et al54,55 estimated that the quality of life during 
pertussis disease for infants and adults decreased to 
0.58 and 0.85, respectively. Assuming a mean disease 
duration of 3 months for infant and reported adult cases 
of pertussis, the QALY losses were estimated at 0.10 
and 0.04 for infants and adults, respectively. A QALY 
loss of 0.02 was assumed for unreported symptomatic
adult cases of pertussis.
Costs of Illness
For the estimation of disease-related costs, distinc-
tions were made between reported and unreported
symptomatic cases of pertussis. Direct and indirect costs 
were included, and national unit costs were obtained
from Oostenbrink et al,56 reflecting the guideline prices 
to be used in Dutch health economic/pharmacoeconomic
analyses. All costs were reported in euros (€s) at 2008 
price levels (2008 conversion factor: €1.00 ≈ $1.40;
US $ rounded to nearest hundred).
The direct costs of reported pertussis cases included
all costs associated with diagnostics, visits to a general 
practitioner (GP), antibiotic treatments, and hospitaliza-
tions. In the analysis, it was assumed that all infants
were treated in the hospital on an ambulatory basis, 
with 1 GP visit and 3 specialist visits (expert panel). For 
reported adult cases, 2 GP visits were assumed.57,58 For
cases treated in the hospital, several diagnostic tests 
were included (polymerase chain reaction [PCR], serol-
ogy, C-reactive protein, chest radiography, and blood
concentration assessment). For the adults treated by a
GP, pertussis was assumed to be diagnosed using culture, 
PCR, or serology. Serology was the most frequently
both cohorts (adults and newborns). Two models were
designed for both cohorts (adults and infants) separately,
which meant that no direct relation existed between the
number of adult and infant cases. Therefore, increasing
the incidence of pertussis in adults to correct for under-
reporting did not result in a corresponding increase in 
cases in infants. The efficacy of an adult immunization 
strategy (eg, cocooning or maternal immunization) was
modeled in the infant cohort by reducing the risk of 
disease by the efficacy of maternally acquired antibodies
and/or by reduced transmission from the parents.
For the analysis of cost-effectiveness, the cohorts in 
the various immunization strategies were assumed to
be fully protected by vaccination, based on the current
vaccination coverage of the Dutch national immuniza-
tion program (96%). A lower rate of vaccine coverage
would not change the cost-effectiveness results, but it 
would affect the number of cases averted and any
budget-consequence calculations potentially linked to 
the cost-effectiveness analysis.
Incidence, Hospitalization, and Mortality Data
Parameter values used in the model were obtained
from the literature, national databases, and expert 
opinions. Because fluctuations in the incidence of per-
tussis occur annually, the mean incidence over a period
of several years was calculated. In particular, the 2002 
to 2005 age-specific pertussis incidence data were ob-
tained from the mandatory notifications to the Centre 
for Infectious Disease Control of the Dutch National 
Institute for Public Health and the Environment
(Bilthoven, the Netherlands). It is generally accepted 
that notifications of pertussis disease do not capture all 
cases of disease and infection; therefore, incidence data 
were corrected for underreporting.4,47–50 For the Neth-
erlands, it has been estimated that the incidence of in-
fection was 6.6% per year in 1995 and 1996.4 Using a 
dynamic transmission model and age-specific data on
underreporting,4 de Vries et al51 estimated that the total 
number of symptomatic pertussis cases (reported and
unreported) in adults is ~200-fold higher than reported
(95% CI, 110–292), resulting in an annual symptomatic 
pertussis incidence of ~3.5% in the adult population. 
Given that some of the previously defined strategies 
were gender specific, the incidence data were analyzed 
for men and women separately, if relevant. For the 
youngest group (0–5 months of age), the annual number 
of hospital admissions was used to estimate the yearly 
incidence of pertussis, which appeared to be slightly
1484 Volume 32 Number 8
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Vaccination Costs
For vaccination, the costs of the vaccine itself and
administration were included in the analyses. The price
for the acellular pertussis vaccine was set at €18.30
($25.60) (corresponding to the retail price in 2008).64
Based on a recently published cost-effectiveness analysis
of vaccination against human papillomavirus, the vac-
cine administration cost was assumed at €6.00 ($8.40).65
Thus, the total immunization cost of a new pertussis 
vaccination strategy was assumed to be €24.30 ($33.40) 
per dose. For the at-birth immunization strategy, vac-
cination costs might be lower because midwives are
already present during birth and administration might
be relatively easy. Lower vaccination prices were inves-
tigated in sensitivity analyses.
Sensitivity Analyses
For the calculation of the base-case cost-effectiveness
of the 3 immunization strategies, uncertainty concerning
vaccine effectiveness, QALY losses, and underreporting
was taken into account in a probabilistic sensitivity
analysis (PSA). In the PSA, a β-distribution for vaccine 
effectiveness (α = 1.2, β = 0.15),22 triangle distributions 
for QALY losses in infants (lower limit, 0.15; mode, 
used test (83% of diagnosed cases).59 Hospitalization 
costs were calculated from the annual number and dura-
tion of hospital admissions (standard and intensive care)
(Table I).52,53 Annually, ~4% of infant cases were assumed
to be treated for 7 to 13 days in the intensive-care unit.53
Finally, it was assumed that only reported cases of pertus-
sis were treated with azithromycin. Because of the lack 
of data, it was assumed conservatively that unreported 
cases incurred no medical costs. An overview of the costs
per pertussis infection is provided in Table II.
Indirect costs consisted of the costs associated with 
loss of productivity by parents who stayed home to care 
for their pertussis-infected child or because they had 
pertussis themselves. In the Netherlands in general, 
mothers have 3 months of maternity leave after delivery; 
therefore, it was assumed that no indirect costs were 
incurred for infants aged 0 to 2 months. For older 
children, a loss of 10 work days for the mother was
assumed.60 For reported and unreported symptomatic
adult cases, losses of 5 and 2.5 days for a pertussis infec-
tion were assumed, respectively.61,62 Using the friction-
costing method, mean indirect costs of €80.69 ($112.97) 
and €50.76 ($71.06) per day were assumed for males
and females, respectively.56,63






Length of Stay, 
Days
Costs Per Stay, 
€ (US $)†
Infants, months‡
0 18.0 18.0 10.2 6644 (9302)
1 55.3 55.3 10.3 5450 (7630)
2 46.8 46.8 6.2 3394 (4752)
3 28.8 28.8 8.1 3556 (4978)
4 13.8 13.8 6.4 2482 (3475)
5 7.0 7.0 5.8 2249 (3149)
6 20.1 8.3 6.1 2595 (3633)
7 10.9 4.5 3.8 1932 (2705)
8 20.6 8.5 6.0 2327 (3258)
9 14.1 5.8 6.9 2675 (3745)
10 12.9 5.3 2.7 1046 (1464)
11 9.7 4.0 3.1 1202 (1683)
Adults§ 358.0 0.7 3.4 1542 (2159)
*Estimates for infants 0 to 5 months of age were based on reported hospitalizations for this age group.
† 2008 Pricing; includes costs of normal and intensive-care admissions (2008 conversion factor: €1.00 ≈ US $1.40).
‡ Cohort of 200,000 infants <1 year of age.
§ Cohort of 2,000,000 adults 25 to 34 years of age.
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fectiveness on the outcomes was assessed by decreasing
vaccine effectiveness by 20% to cope with uncertainty,
in particular related to maternal immunization and
immunization at birth, in the absence of formal clinical 
trials.32,66 The specific impact of the effectiveness of 
maternally acquired antibodies also was investigated. 
For that purpose, effectiveness in infants was decreased
from 89% to 70%. Finally, the QALY losses of unre-
ported adult cases were decreased stepwise from 0.02 
to zero.
In the previously mentioned part of the sensitivity 
analysis, the underreporting factor remained fixed at 
200, as in the base-case analysis (ie, adult symptomatic
pertussis incidence was considered to be increased
200-fold from reported cases in all sensitivity analyses). 
In the second part of the sensitivity analysis, the adjusted 
incidence data were decreased stepwise in the adult
cohort (lowering the underreporting factor). The lower 
limit for the adult pertussis incidence was the num-
ber of reported cases. For the infant cohort, the inci-
dence was increased 3-fold compared with the hospi-
talizations reported in the base case, as reported in a 
study by Crowcroft et al,49 which estimated that pertus-
sis mortality was underestimated 3-fold in England. 
Because mortality was modeled as a function of inci-
0.10; upper limit, 0.05), reported adults (lower limit,
0.06; mode, 0.04; upper limit, 0.02), and unreported 
adults (lower limit, 0.04; mode, 0.02; upper limit, 0.001)
and a normal distribution for the underreporting factor
(mean [SD], 200 [54]) were applied.
Deterministic univariate sensitivity analyses were 
conducted on QALY losses, vaccine costs, indirect costs, 
pertussis transmission rates, vaccine effectiveness, and 
the underreporting factor. For example, the number of 
work days lost by the mother of an infant with pertussis 
was decreased from 10 to 5 days.32,57,61,66 Furthermore,
additional indirect costs for infants 0 to 2 months of 
age were included, assuming that the father might also 
stay at home to care for the infant. Vaccination costs
up to €30.00 ($42.00) and reduced to €18.00 ($25.20)
were investigated. Finally, the QALY loss for infants 
was increased from 0.1 to 0.2.
For industrialized countries, parents appeared to be 
the source of infection in ~50% of cases, which is con-
sistent with findings in the Netherlands.10,19 Because
the infants remained susceptible to other pertussis
sources, the sensitivity analyses tested the scenario
excluding benefits in infants, leaving only the benefits 
of parents for the cocooning and maternal immuniza-
tion strategies. Furthermore, the impact of vaccine ef-
Table II. Estimated direct and indirect pertussis-related costs per pertussis infection.
Variable
Ambulatory Cases Treated
in Hospital, € (US $)
Cases Treated by General 
Practitioner, € (US $)
Direct costs
Diagnostics 221.83 (310.56) 52.48 (73.47)
Visits to general practitioner 22.59 (31.63) 45.18 (63.25)
Visits to specialist 158.67 (222.14) 0
Treatment* 9.40 (13.16), infant
17.24 (24.14), adult
9.40 (13.16), infant 
17.24 (24.14), adult
Indirect costs†
Infants‡ 508.00 (711.20) 508.00 (711.20)
Adult female, reported 254.00 (355.60) 254.00 (355.60)
Adult male, reported 403.00 (564.20) 403.00 (564.20)
Adult female, unreported 127.00 (177.80) 127.00 (177.80)
Adult male, unreported 202.00 (282.80) 202.00 (282.80)
*2008 Pricing; it was assumed that adult cases were treated with cough medicines in addition to antibiotics (2008 conver-
sion factor: €1.00 ≈ US $1.40).
† Cohort of 200,000 infants <1 year of age and cohort of 401,380 adults 25 to 34 years of age.
‡ Work days lost by parents caring for their ill child.
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ICER of €6300 ($8800)/QALY. Excluding unreported
symptomatic cases from our analysis (eg, assuming no 
underreporting) resulted in a significant increase in the
estimated ICER for both immunization strategies (co-
cooning, €211,900 [$296,700]/QALY; maternal im-
munization, €81,600 [$114,200]/QALY). 
From the societal perspective, cocooning and maternal 
immunization were estimated to be cost-saving, with
savings of up to €7200 ($10,100) and €5000 ($7000) 
per QALY gained, respectively. For immunization at
birth, little difference was found between the payer and 
societal perspectives because it was assumed that no 
indirect costs would be incurred for infants 0 to 2 months
of age. The small differences between payer and societal 
perspectives were due only to chance in the uncertainty 
analysis. Finally, when both parents were vaccinated 
during the pregnancy, an ICER of €4400 ($6200)/QALY 
was found from the payer’s perspective.
Deterministic Sensitivity Analysis
The results of the sensitivity analyses from the payer’s
perspective are presented in Table V. For immunization 




The annual numbers of symptomatic pertussis cases 
(reported and unreported) in infants <1 year of age and
adults 25 to 34 years of age were estimated at 258 and
114,955, respectively. After correcting the incidence
data for underreporting, the total number of adult cases 
was 200-fold higher than the number of reported cases
alone (Table I). In the Netherlands, the total pertussis-
related costs for both cohorts combined were estimat-
ed at €971,000 ($1,359,400) and €14,781,900
($20,694,700) annually from the payer and societal 
perspectives, respectively. Pertussis costs per case for 
infants ranged from €660 ($900) for infants 11 months
of age to €7060 ($9900) for infants 0 months of age.
Implementation of each of the investigated immuniza-
tion strategies resulted in a decrease in pertussis incidence 
among infants and/or adults (Table III). Maternal im-
munization appeared to be the most effective strategy 
in protecting infants against pertussis. At-birth immuni-
zation did not appear to be an attractive alternative 
because only a small number of cases among infants
and no cases among adults would be prevented. Co-
cooning appeared to be an attractive alternative to
maternal immunization, although fewer infant pertussis 
cases would be prevented.
The ICERs estimated for adding each of the proposed
immunization strategies to the current Dutch national 
immunization program from the payer and societal
perspectives are presented in Table IV. The incremental 
costs reflected the differences between the total costs 
of a potential pertussis vaccination strategy (disease 
and vaccination costs) and the costs under the current
program (only disease costs considered). The 95% CIs
represented the range of the ICERs by taking into ac-
count all uncertainties in underreporting, vaccine ef-
fectiveness, and QALY losses using the PSA.
From the payer’s perspective, the cost-effectiveness 
of cocooning and maternal immunization were estimated 
to be similar, with ICERs of €4600 ($6400)/QALY (95%
CI, €2200–€17,800 [$3100–$24,900]) and €3500
($4900)/QALY (95% CI, €1700–€15,000 [$2400–
$21,000]), respectively (Table IV). Conversely, immu-
nization at birth was not cost-effective. When directly 
comparing cocooning with maternal immunization,
cocooning was estimated to be cost-effective, with an 
Table III. Estimated number of pertussis cases
averted with the investigated immuniza-
tion strategies compared with the current 
Dutch national immunization program.






55 NA 55 
(18–62)





174 59,089 59,263 
(20,480–
92,510)
NA = not applicable.
*Cohort of 200,000 infants <1 year of age.
† Cohort of 401,380 adults 25 to 34 years of age.
‡ 95% CIs included uncertainty on underreporting, vac-
cine effectiveness, and quality-adjusted life-year losses.
§ For cocooning, the cohort size was set at 401,380.
ǁ For maternal immunization, the cohort size was set at
201,380.
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mated when the vaccine effectiveness was changed. Even 
in that case, the ICER remained under the threshold of 
€20,000 ($28,000)/QALY.
In Table V, outcomes were only shown from the
payer’s perspective. From the societal perspective, co-
cooning and maternal immunization were cost-saving, 
and ICERs are meaningless in such situations. For im-
munization at birth, no differences between the payer
and societal perspectives were found in the analysis.
at birth, all parameters in the sensitivity analyses had 
a relevant impact on the ICER. However, in all scenarios 
analyzed, the ICER of at-birth immunization remained 
higher than the informal Dutch threshold of €20,000
($28,000)/QALY.
For cocooning and maternal immunization, the es-
timated ICERs seemed to be robust. The ICERs varied 
little with changes in QALY loss, indirect cost, vaccine 
cost, and transmission rate. Slight variation was esti-
Table IV. Comparison of base-case estimates of incremental costs and benefits of the investigated immuniza-

























































CS: UL = €7200
CS: UL = $10,100






CS: UL = €5000
CS: UL = $7000
QALY = quality-adjusted life-year; ICER = incremental cost-effectiveness ratio; CS = cost-saving; UL = upper limit of 95% CI.
*2008 Pricing; 95% CI includes uncertainty on underreporting, vaccine effectiveness, and QALY losses (2008 conversion 
factor: €1.00 ≈ US $1.40).
1488 Volume 32 Number 8
Clinical Therapeutics
Table V. Results of the sensitivity analysis on the incremental cost-effectiveness ratio (ICER) for the immuniza-
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QALY = quality-adjusted life-year; NA = not applicable.
*The ICER (2008 pricing) reflects the net costs per QALY gained compared with the current Dutch national immunization 
program; 95% CI includes uncertainty on underreporting, vaccine effectiveness, and QALY losses (2008 conversion fac-
tor: €1.00 ≈ US $1.40).
† Parameters excluded in probabilistic sensitivity analysis.
‡ Vaccine effectiveness was 20% lower than that of the base case.
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the ICER increased slowly. For these 2 strategies, an
80% to 90% decrease in incidence or underreporting
factor still resulted in ICERs that would be considered
favorable in terms of the informal Dutch threshold for 
cost-effectiveness from the societal perspective. Almost
no difference was found between the payer and societal
perspectives when the underreporting factor became 
relatively low.
In the base-case analysis, the assumed QALY loss for
unreported cases was 0.02. Because the exact QALY 
loss in these cases was unknown, the value was decreased 
stepwise from the base case (Figure 3). The ICER ap-
peared to be sensitive for the assumptions on QALY 
losses in the unreported pertussis cases. However, when 
QALY losses approached zero for unreported cases, the 
ICERs increased to possibly unacceptable levels for both
cocooning and maternal immunization from the payer’s
perspective. From the societal perspective, both strate-
gies remained cost-saving, independent of QALY loss
Specific Sensitivity Analysis for Underreporting
The ICER of pertussis immunization may be sensitive 
to the assumptions made about the magnitude of under-
reporting and the utility loss of unreported cases. Further
sensitivity analyses of these aspects are presented in this 
section.
In the base-case analysis, an estimated underreporting
of symptomatic pertussis (incidence 200-fold greater 
than reported cases) was taken into account for adults.
The ICERs of cocooning and maternal immunization 
for different underreporting levels/incidence data in
both the payer and societal perspectives are presented
in Figure 2. It appeared that the ICERs for both im-
munization strategies were highly sensitive to the number
of unreported symptomatic pertussis cases. When the 
incidence was decreased to the number of reported cases 
only, both strategies were associated with unfavorable 
ICERs. However, by decreasing the incidence of symp-







































Maternal immunization, payer’s perspective






Figure 2. Sensitivity analyses of the cocooning and maternal immunization strategies, showing the impact of 
changes in the incidence of pertussis among adults on the incremental cost-effectiveness ratio
(ICER) per quality-adjusted life-year (QALY) of the 2 strategies. The horizontal axis shows the cor-
rection factors for underreporting among adults (percentages in parentheses reflect the estimated
incidence after correcting for underreporting). (2008 Conversion factor: €1.00 ≈ US $1.40.)
1490 Volume 32 Number 8
Clinical Therapeutics
ternative to maternal immunization, although ~30%
fewer infant pertussis cases might be prevented. Both
cocooning and maternal immunization would be simi-
larly and highly cost-effective according to the informal
Dutch threshold for cost-effectiveness.31 Immunization
at birth was estimated not to be cost-effective. 
These cost estimates are consistent with those re-
ported by de Greeff et al58 for the Netherlands and 
those reported by Lee et al67 in their analysis of pertussis 
immunization in Germany, for both infant and adult 
cases. In particular, de Greeff et al recently calculated 
pertussis-related costs for 5 age groups (<1 year,
1–9 years, 10–19 years, 20–44 years, and ≥45 years) in 
the Netherlands. In the present study, pertussis costs
were calculated using other data sources and more detail 
for costs among infants. For example, the cost estimates
were stratified per month for infants <1 year of age, 
resulting in costs per pertussis case aged 0 to 11 months 
ranging from €660 ($900) to €7060 ($9900) per case 
versus an overall cost of €3572 ($5000) per infant case 
reported by de Greeff et al.
(data not shown because the absolute negative values 
of ICERs are meaningless). 
DISCUSSION
This study estimated the cost-effectiveness of adding 
new pertussis immunization strategies to the current
Dutch national immunization program. In particular,
the strategies of immunization at birth, cocooning, and
maternal immunization were investigated. The introduc-
tion of a new pertussis immunization strategy should 
primarily be aimed at reducing the incidence among 
infants; however, benefits in other age groups also should
be considered. To our knowledge, this is the first con-
sistent comparison of 3 relevant strategies that can be 
considered to further reduce the incidence of pertussis.
In the base-case analysis, it was estimated that ma-
ternal immunization might be the most effective strategy 
in preventing pertussis in infants. Because of the assumed
limited vaccine effectiveness in infants, immunization 
at birth did not appear to be as effective. By saving more 

























Figure 3. Sensitivity analyses of the cocooning and maternal immunization strategies showing the impact of 
quality-adjusted life-year (QALY) losses among unreported adult cases of pertussis on the estimated 
incremental cost-effectiveness ratio (ICER) from the payer’s perspective. (2008 Conversion factor: 
€1.00 ≈ US $1.40.)
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unreported symptomatic cases might have been too
conservative.
Maternal immunization appeared to be the most
effective strategy for protecting infants. This strategy 
might prevent ~1.5 times more infant pertussis cases 
than the cocooning strategy. This is mainly due to the
assumption about effectiveness conferred by maternally 
acquired antibodies from birth until the infant is vac-
cinated within the current Dutch national immunization
program. Although no clinical data on the effectiveness
and tolerability of maternal immunization are yet availa-
ble, several studies have reported that placental transfer 
of antibodies against pertussis may be effective.40,41
Currently, 2 registered clinical trials have begun recruit-
ing participants for testing maternal immunization with
acellular pertussis vaccines.68
Decreasing the effectiveness of maternal antibodies 
from 89% to 70% resulted in a slight increase in the
ICER (from €3500 [$4900]/QALY to €3600 [$5000]/
QALY). The main disadvantage of maternal immuniza-
tion was the rapid decrease in antibody titers after
vaccination. Therefore, it was assumed that mothers
should be vaccinated during every pregnancy to protect
infants with maternally acquired antibodies. However,
little is known about the tolerability of short-interval
(eg, ~2-year) booster immunization at older age. Fur-
thermore, it was assumed that maternal antibodies (in 
combination with routine infant vaccination) would
provide a high level of protection during the first
4 months of life (89% effectiveness). With an alternative 
and more conservative assumption, limiting protection 
with maternal antibodies to 2 months would increase
the cost-effectiveness ratios almost to the level reported
for cocooning.
Implementation of the cocooning strategy would not
provide full protection for newborns. Indeed, transmis-
sion from the mother in the first 2 weeks of the infant’s
life might not be prevented because of the delay in
vaccine-induced immunity. The newborn would still be 
susceptible to other infectious sources, such as grand-
parents and other visitors. However, this strategy was
the only one of the analyzed strategies that currently 
could be implemented because no vaccine has yet been 
approved for use in newborns or pregnant women. It
also offers other advantages, such as indirect protection
to contacts outside the family (both children and adults). 
This herd-immunity effect, which also may play a role
in the other strategies, is not taken into account in this 
static model. It was believed that investigating the
Sensitivity analysis showed that assumptions on
vaccine price, transmission from parents to infants, and
QALY losses had almost no impact on the results for
the 3 immunization strategies. However, the ICER ap-
peared to be sensitive to the values for vaccine effective-
ness and underreporting.  Decreasing the total pertussis
incidence to 0.35% in adults, as reported by Ward et
al22 in the United States, resulted in ICERs of €43,400 
($60,800)/QALY and €28,000 ($39,200)/QALY for
cocooning and maternal immunization, respectively, 
from the payer’s perspective. From the societal perspec-
tive, ICERs were €34,900 ($48,900)/QALY and €24,800 
($34,700)/QALY, respectively. The ICERs increased to 
€211,900 ($296,700)/QALY and €81,600 ($114,200)/
QALY for cocooning and maternal immunization, re-
spectively, when unreported cases were not taken into 
account in the analysis.
In the base-case analysis, the number of symptomatic 
pertussis cases was 200-fold higher than that reported 
by de Vries and Postma51 for the period 1996 to 2000.
It was assumed that for the period 2002 to 2005, symp-
tomatic pertussis would also be 200-fold higher than
reported. By using this underreporting factor, it was 
estimated that the incidence of symptomatic pertussis 
in adults 25 to 34 years of age was ~3.5% annually. 
Recently, Nooitgedagt et al40 reported an annual inci-
dence of symptomatic pertussis of ~1.5% (95% CI, 
1.1%–4.3%) among pregnant women in the Nether-
lands, which was lower than the estimates in this study. 
However, this study was not designed to obtain incidence
data, and the results should be interpreted with caution 
because of the small sample size, inclusion bias, missing 
sample data, and annual fluctuations in incidence data.
The sensitivity analysis with this model found that
decreasing the underreporting factor by 80% to 90% 
still resulted in ICERs below the informal Dutch thresh-
old (€20,000 [$28,000]/QALY) for cocooning and 
maternal immunization.
Although uncertainty exists regarding the incidence 
of symptomatic pertussis, significantly lower incidence 
data still resulted in favorable ICERs. In the present 
study, a 20- to 30-fold increase in the incidence of re-
ported cases resulted in ICERs below the informal Dutch
threshold (€20,000 [$28,000]/QALY) for cocooning 
and maternal immunization. Even lower ICERs could 
be obtained if medical costs for unreported symptomatic 
cases had been included in the analysis. However, this
was not possible because of the lack of data. Further-
more, due to the lack of data, QALY losses for these 
1492 Volume 32 Number 8
Clinical Therapeutics
The present study did not include costs and QALY losses
due to adverse events of vaccination. Because the adverse
events associated with pertussis vaccination are gener-
ally mild, no serious QALY losses or costs would be
expected. However, although these adverse events are 
rare, in the case of population-based vaccination pro-
grams, the total costs and QALY losses in the population 
due to adverse events might be substantial. Including 
the QALY losses and costs of adverse events might 
slightly increase the estimated ICERs of the analyzed
immunization strategies.
Finally, this study took into account only the benefits 
of a reduced incidence of pertussis. However, because
combination vaccines containing acellular pertussis as
only one element are available for adults, additional
benefits might be expected if combinations were used. 
Use of combination vaccines would be consistent with 
general recommendations on booster vaccinations 
against tetanus and specific recommendations for travel-
ers (eg, diphtheria). Including additional benefits (eg, 
preventing other diseases in adults) will further improve
the estimated ICERs of the cocooning and maternal 
immunization strategies. Alternatively, one could argue 
that only the marginal price of the pertussis component 
of the combination vaccine should be used in an analysis 
such as this one, which would improve the estimated
ICERs.
CONCLUSIONS
This study estimated that both cocooning and maternal 
immunization were cost-effective (and even cost-saving)
interventions that might be added to the current Dutch 
national immunization program. These estimates were 
mainly due to reductions in cases among the parents, 
which likely would not be severe and therefore would 
remain unreported. Immunization at birth was not
cost-effective. Cocooning was the most expensive in-
tervention to implement; however, it resulted in the
highest number of QALYs gained (mainly in adults). 
Maternal immunization would offer better protection
of infants, due to maternally acquired antibodies. 
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